It’s Deal Time: Aurobindo on M&A, Divestment Path
Domestic Formulations Foray On Cards
What value do PE funds see in Aurobindo Pharma’s injectables business as the company looks for a partner? Why is Aurobindo looking for acquisitions in India as it sets a domestic revenue target of $133m in three years from the formulations business? Scrip takes a look.
